Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.44 |
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | HTR1A | P08908 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | HTR6 | P50406 | 5/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD5 | P21918 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6995184 | 0.93 | HTR7 (0.48) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6994107 | 0.92 | KCNH2 (0.51) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6992836 | 0.92 | HTR7 (0.40) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6997041 | 0.91 | HTR7 (0.46) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6997847 | 0.88 | HTR7 (0.47) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6995585 | 0.87 | DRD4 (0.43) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6992333 | 0.87 | HTR1A (0.50) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6999266 | 0.83 | DRD2 (0.47) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6997331 | 0.82 | HTR1A (0.54) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6987487 | 0.81 | DRD2 (0.52) | HTR7DRD2HTR1AHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-0749967-B1 | Substituted benzothiazine derivative | SUNTORY LTD (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6316442-B1 | TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES | SUNTORY LIMITED (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5874429-A | ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS | SUNTORY LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0749967-A1 | Substituted benzothiazine derivative | SUNTORY LIMITED (JP) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | HTR7 24/4885DRD2 402/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.